Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
Summary. A variety of definitions of major bleeding have been used in published clinical studies, and this diversity adds to the difficulty in comparing data between trials and in performing meta-analyses. In the first step towards unified definitions of bleeding complications, the definition of major bleeding in non-surgical patients was discussed at the Control of Anticoagulation Subcommittee of the International Society on Thrombosis and Haemostasis. Arising from that discussion, a definition was developed that should be applicable to studies with all agents that interfere with hemostasis, including anticoagulants, platelet function inhibitors and fibrinolytic drugs. The definition and the text that follows have been reviewed and approved by the cochairs of the subcommittee and the revised version is published here. The intention is to also seek approval of this definition from the regulatory authorities.
Schulman
S
S
Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden. schulms@mcmaster.ca
Kearon
C
C
D000925:Anticoagulants / Q000009:adverse effects* / Q000494:pharmacology; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000494:pharmacology; D006405:Hematology / Q000592:standards; D006470:Hemorrhage / Q000139:chemically induced* / Q000401:mortality / Q000628:therapy; D006487:Hemostasis; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000494:pharmacology; D011183:Postoperative Complications
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors